Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department()

AIMS: Ibutilide is a rapid-acting antiarrhythmic drug with worldwide use for conversion of recent-onset atrial fibrillation. Vernakalant, approved in the EU in 2010, is likewise used intravenously, with proven efficacy and safety compared with placebo and amiodarone in randomized clinical trials. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, Alexander, Niederdoeckl, Jan, Skyllouriotis, Ekaterini, Schuetz, Nikola, Herkner, Harald, Weiser, Christoph, Laggner, Anton N., Domanovits, Hans, Spiel, Alexander O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400093/
https://www.ncbi.nlm.nih.gov/pubmed/28175295
http://dx.doi.org/10.1093/europace/euw052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400093/
https://www.ncbi.nlm.nih.gov/pubmed/28175295
http://dx.doi.org/10.1093/europace/euw052

Ejemplares similares